DGAP-Adhoc Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
|
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) |
Osaka, Japan, February 4, 2021 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021*1, as below.
1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2021
(millions of yen)
| Revenue |
Core Operating Profit |
Operating profit |
Profit before income taxes |
Net profit attributable to owners of the Company |
Basic earnings per share |
Core EPS | |
| Previous Forecast (A)*** | 3,250,000 | 984,000 | 434,000 | 258,000 | 124,000 | 79.39 yen | 420 yen |
| Revised Forecast (B) | 3,250,000 | 984,000 | 434,000 | 258,000 | 180,500 | 115.56 yen | 420 yen |
| Discrepancy (B-A) | ― | ― | ― | ― | +56,500 | ― | ― |
| Change % | ― | ― | ― | ― | +45.6% | ― | ― |
*** Announced on October 29, 2020.
Diesen Artikel teilen
